Key points are not available for this paper at this time.
Bendamustine showed an encouraging high response rate across the two major PTCL subtypes, independent of age and prior treatment, with acceptable toxicity in refractory or relapsed T-cell lymphoma.
Damaj et al. (Tue,) studied this question.